Effects of Inhaled Corticosteroids on the Innate Immunological Response to Pseudomonas aeruginosa Infection in Patients with COPD
Authors:
- Noemi Cerón-PisaNCNoemi Cerón-Pisa
- Hanaa ShafiekHSHanaa Shafiek
- Aina Martín-MedinaAMAina Martín-Medina
- Javier VerdúJVJavier Verdú
- Elena Jordana-LluchEJElena Jordana-Lluch
- Maria Escobar-SalomMEMaria Escobar-Salom
- Isabel M. BarcelóIBIsabel M. Barceló
- Carla López-CausapéCLCarla López-Causapé
- Antonio OliverAOAntonio Oliver
- Carlos JuanCarlos Juan
- Amanda IglesiasAIAmanda Iglesias
- Borja G. CosíoBorja G. Cosío
Open Access
- 23 July 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8127
Abstract
Inhaled corticosteroids (ICS) use is associated with an increased risk of Pseudomonas aeruginosa (PA) infection in patients with COPD. We aimed to evaluate the effects of ICS on alveolar macrophages in response to PA in COPD patients with and without baseline ICS treatment (COPD and COPD + ICS, respectively) as well as smoker and nonsmoker controls. To do so, cells were infected with PA and cotreated with budesonide (BUD) or fluticasone propionate (FLU). The analysis of NF-κB and c-jun activity revealed a significant increase in both factors in response to PA cotreated with BUD/FLU in smokers but not in COPD or COPD + ICS patients when compared with PA infection alone. The expression of Toll-like receptor 2 (TLR2) and the transcription factor c-jun were induced upon PA infection in nonsmokers only. Moreover, in the smoker and COPD groups, there was a significant increase in TLR2 and a decrease in c-jun expression when treated with BUD/FLU after PA infection, which were not observed in COPD + ICS patients. Therefore, the chronic use of ICS seemingly makes the macrophages tolerant to BUD/FLU stimulation compared with those from patients not treated with ICS, promoting an impaired recognition of PA and activity of alveolar macrophages in terms of altered expression of TLR2 and cytokine production, which could explain the increased risk of PA infection in COPD patients under ICS treatment.Keywords
Funding Information
- Menarini 2018 and 866-2019 SEPAR (Sociedad Española de Neumología y Cirugía Torácica)
- Liberi 2022 Program (Instituto de Investigación Sanitaria de las Islas Baleares)
This publication has 43 references indexed in Scilit:
- Inhaled corticosteroids in COPD and the risk of serious pneumoniaThorax, 2013
- Influence of Age, Past Smoking, and Disease Severity on TLR2, Neutrophilic Inflammation, and MMP-9 Levels in COPDMediators of Inflammation, 2013
- Lung CD8+ T cells in COPD have increased expression of bacterial TLRsRespiratory Research, 2013
- IκB kinase–driven nuclear factor-κB activation in patients with asthma and chronic obstructive pulmonary diseaseJournal of Allergy and Clinical Immunology, 2011
- Cigarette Smoking and InflammationJournal of Dental Research, 2011
- Dampening Host Sensing and Avoiding Recognition in Pseudomonas aeruginosa PneumoniaBioMed Research International, 2011
- Budesonide enhances Toll-like receptor 2 expression in activated bronchial epithelial cellsInhalation Toxicology, 2010
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Fatty acid-binding proteins: role in metabolic diseases and potential as drug targetsNature Reviews Drug Discovery, 2008
- Cigarette smoke suppresses Th1 cytokine production and increases RSV expression in a neonatal modelAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006